NEJM:常见变异性免疫缺陷病的IKAROS突变

2016-03-22 MedSci MedSci原创

常见变异性免疫缺陷病(CVID)是指无明显诱因的低丙球蛋白血症。在大多数病例中的遗传原因尚不明确,只有少于10%的患者有家庭疾病史。大多数病人有正常数量的B细胞,但是缺乏浆细胞。

常见变异性免疫缺陷病(CVID)是指无明显诱因的低丙球蛋白血症。在大多数病例中的遗传原因尚不明确,只有少于10%的患者有家庭疾病史。大多数病人有正常数量的B细胞,但是缺乏浆细胞。

我们使用全外显子基因测序和基于阵列的比较基因组杂交技术评估CVID病人和低B细胞数病人的分型。使用凝胶电泳迁移实验(EMSA)和共焦显微镜分析突变的DNA结合蛋白。

结果发现,IKZF1有6种不同的杂合突变,在6个家庭的29人中发现基因编码转录因子IKAROS。其中两个家庭的突变是从上一代产生的新生突变。IKAROS DNA结合域的所有突变类型包括4个氨基酸替换,1个基因缺失,和一个4.7-Mb多基因缺失。EMSA和共焦显微镜下,错义突变的蛋白质未能结合目标DNA序列,然而,它们未能阻止野生型IKAROS基因的结合。家庭成员的研究显示了B细胞和血清免疫球蛋白的大量缺失。2个病人的骨髓穿刺显示早期前体B细胞明显减少,但出现了浆细胞。29个病人中的2个发展为急性淋巴细胞白血病。
 
IKAROS转录因子的杂合突变导致了CVID的常染色体显性遗传,与B-cell数量显著减少相关。

原始出处:

Hye Sun Kuehn, Ph.D., Bertrand Boisson, et al,Loss of B Cells in Patients with Heterozygous Mutations in IKAROS,N Engl J Med 2016; 374:1032-1043March 17, 2016

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1744429, encodeId=01911e44429f4, content=<a href='/topic/show?id=17929616fd' target=_blank style='color:#2F92EE;'>#Ikaros#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9616, encryptionId=17929616fd, topicName=Ikaros)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8cf35388218, createdName=xuqianhua, createdTime=Sun Jun 26 17:47:00 CST 2016, time=2016-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342342, encodeId=4eff1342342c8, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Thu Mar 24 03:47:00 CST 2016, time=2016-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364102, encodeId=7c86136410293, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Thu Mar 24 03:47:00 CST 2016, time=2016-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488952, encodeId=139c148895283, content=<a href='/topic/show?id=7df32913871' target=_blank style='color:#2F92EE;'>#免疫缺陷#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29138, encryptionId=7df32913871, topicName=免疫缺陷)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=631b8488299, createdName=rebeccajiejie, createdTime=Thu Mar 24 03:47:00 CST 2016, time=2016-03-24, status=1, ipAttribution=)]
    2016-06-26 xuqianhua
  2. [GetPortalCommentsPageByObjectIdResponse(id=1744429, encodeId=01911e44429f4, content=<a href='/topic/show?id=17929616fd' target=_blank style='color:#2F92EE;'>#Ikaros#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9616, encryptionId=17929616fd, topicName=Ikaros)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8cf35388218, createdName=xuqianhua, createdTime=Sun Jun 26 17:47:00 CST 2016, time=2016-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342342, encodeId=4eff1342342c8, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Thu Mar 24 03:47:00 CST 2016, time=2016-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364102, encodeId=7c86136410293, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Thu Mar 24 03:47:00 CST 2016, time=2016-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488952, encodeId=139c148895283, content=<a href='/topic/show?id=7df32913871' target=_blank style='color:#2F92EE;'>#免疫缺陷#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29138, encryptionId=7df32913871, topicName=免疫缺陷)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=631b8488299, createdName=rebeccajiejie, createdTime=Thu Mar 24 03:47:00 CST 2016, time=2016-03-24, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1744429, encodeId=01911e44429f4, content=<a href='/topic/show?id=17929616fd' target=_blank style='color:#2F92EE;'>#Ikaros#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9616, encryptionId=17929616fd, topicName=Ikaros)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8cf35388218, createdName=xuqianhua, createdTime=Sun Jun 26 17:47:00 CST 2016, time=2016-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342342, encodeId=4eff1342342c8, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Thu Mar 24 03:47:00 CST 2016, time=2016-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364102, encodeId=7c86136410293, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Thu Mar 24 03:47:00 CST 2016, time=2016-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488952, encodeId=139c148895283, content=<a href='/topic/show?id=7df32913871' target=_blank style='color:#2F92EE;'>#免疫缺陷#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29138, encryptionId=7df32913871, topicName=免疫缺陷)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=631b8488299, createdName=rebeccajiejie, createdTime=Thu Mar 24 03:47:00 CST 2016, time=2016-03-24, status=1, ipAttribution=)]
    2016-03-24 lsndxfj
  4. [GetPortalCommentsPageByObjectIdResponse(id=1744429, encodeId=01911e44429f4, content=<a href='/topic/show?id=17929616fd' target=_blank style='color:#2F92EE;'>#Ikaros#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9616, encryptionId=17929616fd, topicName=Ikaros)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8cf35388218, createdName=xuqianhua, createdTime=Sun Jun 26 17:47:00 CST 2016, time=2016-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342342, encodeId=4eff1342342c8, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Thu Mar 24 03:47:00 CST 2016, time=2016-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364102, encodeId=7c86136410293, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Thu Mar 24 03:47:00 CST 2016, time=2016-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488952, encodeId=139c148895283, content=<a href='/topic/show?id=7df32913871' target=_blank style='color:#2F92EE;'>#免疫缺陷#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29138, encryptionId=7df32913871, topicName=免疫缺陷)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=631b8488299, createdName=rebeccajiejie, createdTime=Thu Mar 24 03:47:00 CST 2016, time=2016-03-24, status=1, ipAttribution=)]

相关资讯

JCI:联合化疗可有效治疗CVID患者继发性肺疾病

Wisconsin医科大学和Wisconsin研究所儿童医院的一个研究团队针对自身具有基础免疫缺陷(被称作普通易变型免疫缺陷,CVID)患者发生潜在致死性肺病定义了一个新的治疗方法,其研究结果发表在Clinical Immunology上。 普通易变型免疫缺陷(CVID)是最常见的原发性免疫缺陷病,需要定期药物治疗,特别是免疫球蛋白(抗体)的替代疗法。在免疫球蛋白治疗方案下,CVID患者因感染导